IL6 and gout: In a randomized, double-blind, placebo-controlled pilot study, Huang et al. (96) explored the effects of febuxostat on serum inflammatory markers such as IL-6, IL-17, and TNF-α in 156 Chinese patients with gout and hyperuricemia.